Prognostic models for progression-free survival in atypical meningioma: Comparison of machine learning-based approach and the COX model in an Asian multicenter study.

Journal: Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology
PMID:

Abstract

BACKGROUND AND PURPOSE: Atypical meningiomas are prevalent intracranial tumors with varied prognoses and recurrence rates. The role of adjuvant radiotherapy (ART) in atypical meningiomas remains debated. This study aimed to develop and validate a prognostic model incorporating machine learning techniques and clinical factors to predict progression-free survival (PFS) in patients with atypical meningiomas and assess the impact of ART.

Authors

  • Dowook Kim
    Department of Radiation Oncology, Chungnam National University Hospital, Chungnam National University College of Medicine, Daejeon, South Korea.
  • Yeseul Kim
    School of Chemical Engineering, Yeungnam University, Gyeongsan 38541, Republic of Korea.
  • Wonmo Sung
    Department of Biomedical Engineering and of Biomedicine & Health Sciences, College of Medicine, The Catholic University of Korea, Seoul, South Korea.
  • In Ah Kim
    Department of Radiation Oncology, Seoul National University Bundang Hospital, Seongnam, 13620, Korea.
  • Jaeho Cho
    Department of Radiation Oncology, Yonsei Cancer Center, Heavy Ion Therapy Research Institute, Yonsei University College of Medicine, Seoul, South Korea.
  • Joo Ho Lee
    Department of Radiation Oncology and Cancer Research Institute, Seoul National University Hospital, Seoul, Korea.
  • Clemens Grassberger
    Department of Radiation Oncology, University of Washington, Seattle, Washington.
  • Hwa Kyung Byun
    Department of Radiation Oncology, Yonsei Cancer Center, Yonsei University College of Medicine, 50-1 Yonsei-ro, Seodaemun-gu, Seoul, 03722, South Korea.
  • Won Ick Chang
    Department of Radiation Oncology, Seoul National University Hospital, Seoul National University College of Medicine, Seoul, South Korea.
  • Leihao Ren
    Department of Neurosurgery of Huashan Hospital, State Key Laboratory of Medical Neurobiology, MOE Frontiers Center for Brain Science and Institutes of Brain Science, Fudan University, Shanghai, China.
  • Ye Gong
    Department of Neurosurgery of Huashan Hospital, State Key Laboratory of Medical Neurobiology, MOE Frontiers Center for Brain Science and Institutes of Brain Science, Fudan University, Shanghai, China. gong_ye@fudan.edu.cn.
  • Chan Woo Wee
    Department of Radiation Oncology, Yonsei Cancer Center, Heavy Ion Therapy Research Institute, Yonsei University College of Medicine, Seoul, South Korea; Brain Research Institute, Yonsei University College of Medicine, Seoul, Korea. Electronic address: wcw0108@hanmail.net.
  • Lingyang Hua
    Department of Neurosurgery of Huashan Hospital, State Key Laboratory of Medical Neurobiology, MOE Frontiers Center for Brain Science and Institutes of Brain Science, Fudan University, Shanghai, China.
  • Hong In Yoon
    Department of Radiation Oncology, Yonsei Cancer Center, Heavy Ion Therapy Research Institute, Yonsei University College of Medicine, Seoul, South Korea; Brain Research Institute, Yonsei University College of Medicine, Seoul, Korea. Electronic address: yhi0225@yuhs.ac.